MedPath

Outcome of Steroid Therapy for Myocardial Inflammation in Scleroderma

Phase 2
Completed
Conditions
Myocardial Inflammation
Interventions
Registration Number
NCT03607071
Lead Sponsor
Khon Kaen University
Brief Summary

Primary myocardial involvement is common in scleroderma, effected to pericardium, vascular, conducting defect and especially myocardium. Cardiac MRI is widely used for assessment of cardiac involvement in scleroderma, both structural and functional pathology. Cardiac MRI has a diagnostic accuracy of 85% for the detection of myocardial inflammation. Nowadays, the treatment of myocardial inflammation in scleroderma is uncertain. The investigator's study aims to define the cardiac outcome after moderate dose steroid therapy in the patients who have myocardial inflammation detection by cardiac MRI.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria

• The adult scleroderma patients who were defined as having myocardial inflammation by cardiac MRI.

Exclusion Criteria
  • Current infection that needs systemic antibiotic therapy
  • Active viral hepatitis B or C
  • Uncontrolled diabetes mellitus

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PrednisolonePrednisolone and taperThe patient who has detected myocardial inflammation from cardiac MRI from baseline is given prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
Primary Outcome Measures
NameTimeMethod
Changing of degree of myocarditis evaluated by cardiac MRI after treatment compare to baseline24 weeks

Myocarditis is defined as inflammatory disease of the myocardium according to the cardiac MRI Lake Louise criteria at least 2 of the following criteria:

1. Regional or global myocardial signal intensity increased in the T2-weighted images;

2. Increased global myocardial early enhancement ratio between the myocardium and skeletal muscle in the gadolinium-enhanced T1-weighted images; and,

3. At least 1 focal lesion with nonischemic regional distribution in the inversion-recovery-prepared, gadolinium-enhanced, T1-weighted images (delayed enhancement).

Response to treatment is defined as any reducing of degree of myocarditis without any progression of myocardial fibrosis or scarring when compared to the cardiac MRI baseline

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Medicine, Faculty of Medicine, Khon Kaen University

🇹🇭

Khon Kaen, Thailand

© Copyright 2025. All Rights Reserved by MedPath